TY - JOUR T1 - Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC鈥擱eal World Efficacy JO - Cancers UR - http://dx.doi.org/10.3390/cancers13194846 PY - 2021/09/28 AU - Mouritzen MT AU - Carus A AU - Ladekarl M AU - Meldgaard P AU - Nielsen AWM AU - Livbjerg A AU - Larsen JW AU - Skuladottir H AU - Kristiansen C AU - Wedervang K AU - Schytte T et al ED - DO - DOI: 10.3390/cancers13194846 PB - MDPI AG VL - 13 IS - 19 SP - 4846 EP - 4846 Y2 - 2025/05/16 ER -